Literature DB >> 30147867

Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Erin Cleveland1, Andrew Bandy2, Lisa B VanWagner1,3.   

Abstract

Entities:  

Year:  2018        PMID： 30147867      PMCID： PMC6103635          DOI： 10.1002/cld.716

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  14 in total

1.  Liver fibrosis scores predict liver disease mortality in the United States population.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Hepatology       Date:  2017-05-16       Impact factor: 17.425

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

3.  Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

Authors:  Julie Parkes; Paul Roderick; Scott Harris; Christopher Day; David Mutimer; Jane Collier; Martin Lombard; Graeme Alexander; John Ramage; Geoffrey Dusheiko; Mark Wheatley; Carol Gough; Alastair Burt; William Rosenberg
Journal:  Gut       Date:  2010-07-30       Impact factor: 23.059

4.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

5.  Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity.

Authors:  Jun Chen; Meng Yin; Jayant A Talwalkar; Jennifer Oudry; Kevin J Glaser; Thomas C Smyrk; Véronique Miette; Laurent Sandrin; Richard L Ehman
Journal:  Radiology       Date:  2016-11-18       Impact factor: 11.105

6.  Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.

Authors:  Charlie C Park; Phirum Nguyen; Carolyn Hernandez; Ricki Bettencourt; Kimberly Ramirez; Lynda Fortney; Jonathan Hooker; Ethan Sy; Michael T Savides; Mosab H Alquiraish; Mark A Valasek; Emily Rizo; Lisa Richards; David Brenner; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterology       Date:  2016-10-27       Impact factor: 22.682

7.  Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Rocio Lopez; Tarek Abu-Rajab Tamimi; Lisa Yerian; Yoon-Mi Chung; Michael Berk; Renliang Zhang; Thomas M McIntyre; Stanley L Hazen
Journal:  J Lipid Res       Date:  2010-07-14       Impact factor: 5.922

8.  Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).

Authors:  Siddharth Verma; Donald Jensen; John Hart; Smruti R Mohanty
Journal:  Liver Int       Date:  2013-06-13       Impact factor: 5.828

9.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

10.  Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.

Authors:  Thierry Poynard; Vlad Ratziu; Frederic Charlotte; Djamila Messous; Mona Munteanu; Françoise Imbert-Bismut; Julien Massard; Luninita Bonyhay; Mohamed Tahiri; Dominique Thabut; Jean François Cadranel; Brigitte Le Bail; Victor de Ledinghen
Journal:  BMC Gastroenterol       Date:  2006-11-10       Impact factor: 3.067
View more
  13 in total

1.  Liver transplantation in the era of non-alcoholic fatty liver disease/metabolic (dysfunction) associated fatty liver disease: the dilemma of the steatotic liver graft on transplantation and recipient survival.

Authors:  Seren M Gedallovich; Daniela P Ladner; Lisa B VanWagner
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

2.  Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Julio Cesar Fernandez-Travieso; Ivan Rodriguez-Perez; Caridad Ruenes-Domech; Jose lIlnait-Ferrer; Lilia Fernandez-Dorta; Sarahi Mendoza-Castano
Journal:  Gastroenterology Res       Date:  2020-04-22

Review 3.  Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH.

Authors:  Brian Finan; Sebastian D Parlee; Bin Yang
Journal:  Mol Metab       Date:  2020-12-23       Impact factor: 7.422

4.  Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study.

Authors:  Yariv Gerber; Lisa B VanWagner; Kristine Yaffe; James G Terry; Jamal S Rana; Jared P Reis; Stephen Sidney
Journal:  BMC Gastroenterol       Date:  2021-03-02       Impact factor: 3.067

5.  Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study.

Authors:  Silvia Bettini; Roberto Serra; Roberto Fabris; Chiara Dal Prà; Francesca Favaretto; Francesca Dassie; Claudio Duso; Roberto Vettor; Luca Busetto
Journal:  Eat Weight Disord       Date:  2021-04-03       Impact factor: 4.652

6.  The Marine Microalga, Tisochrysis lutea, Protects against Metabolic Disorders Associated with Metabolic Syndrome and Obesity.

Authors:  Claire Mayer; Léo Richard; Martine Côme; Lionel Ulmann; Hassan Nazih; Benoît Chénais; Khadija Ouguerram; Virginie Mimouni
Journal:  Nutrients       Date:  2021-01-28       Impact factor: 5.717

7.  Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease.

Authors:  Caridad Ruenes Domech; Julio Cesar Fernandez Travieso; Zaily Dorta Guridi; Marlen Ivón Castellanos Fernández; Sacha Lazo Del Vallín; Anaisa Rojas Carralero; Elena Ferrer Batallie; Aimeé Marcia Alvarez Alvarez; Lilia Fernández Dorta; José Illnait Ferrer; Sarahi Mendoza Castaño; Maytee Robaina García; Gladys Jiménez Rivero; Yeni Veliz Alvarez
Journal:  Clin Exp Hepatol       Date:  2021-03-12

8.  Breath biomarkers of insulin resistance in pre-diabetic Hispanic adolescents with obesity.

Authors:  Mohammad S Khan; Suzanne Cuda; Genesio M Karere; Laura A Cox; Andrew C Bishop
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

9.  Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?

Authors:  Hayatul Najaa Miptah; Anis Safura Ramli; Mariam Mohamad; Hilwati Hashim; Zahirah Tharek
Journal:  BMC Fam Pract       Date:  2020-11-20       Impact factor: 2.497

10.  In situ visualization of peroxisomal viscosity in the liver of mice with non-alcoholic fatty liver disease by near-infrared fluorescence and photoacoustic imaging.

Authors:  Yongqing Zhou; Ping Li; Xin Wang; Chuanchen Wu; Nannan Fan; Xiaoning Liu; Lijie Wu; Wei Zhang; Wen Zhang; Zhenzhen Liu; Bo Tang
Journal:  Chem Sci       Date:  2020-10-06       Impact factor: 9.825
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.